Company News, Video 02 Feb 2026 February 2026 Orthocell Investor Webinar Replay  In this webinar, Orthocell Chair, John Van Der Wielen, CEO and MD, Paul Anderson, and Independent Director, Dr Ravi Thadani provide an important operational update… Orthocell
Company News, Media 26 Jan 2026 Orthocell Co-Founder Professor Minghao Zheng Appointed Member of the Order of Australia (AM) Orthocell proudly congratulates our Co-Founder and Chief Scientific Officer, Professor Minghao Zheng AM, on being appointed a Member of the… Orthocell
Company News 19 Jan 2026 Quarterly Report for period ended 31 December 2025 Orthocell has today released its Quarterly Report for the period ended 31 December 2025 – a quarter marked by continued revenue growth and accelerating U.S. commercialisation. Orthocell
Company News 16 Jan 2026 Ausbiz | Interview with John Van Der Wielen  Orthocell Chairman John Van Der Wielen recently spoke with ausbiz about the Company’s strategic investment in Marine Biomedical and the rationale behind securing global distribution rights to PearlBone™.  Orthocell
Company News 06 Jan 2026 Orthocell Records Seventh Consecutive Quarter of Record Revenue at $3.2m For the quarter ended 31 December 2025, the Company achieved record quarterly revenue of $3.2 million, representing a 7.0% increase on the… Orthocell
Company News 15 Dec 2025 Orthocell Submits Regulatory Application for Remplirâ„¢ into EU and UK Orthocell has submitted a regulatory application to the British Standards Institution (BSI) seeking approval to commercially distribute Remplirâ„¢ in the… Orthocell
Company News 10 Dec 2025 Orthocell Strengthens Asian Growth Platform with First Commercial Sales in Hong Kong Orthocell has announced that it has completed the first commercial sales of Remplirâ„¢ in Hong Kong, representing a key milestone… Orthocell
Company News 20 Nov 2025 Remplir™ Nerve Sparing Prostate Cancer Surgery Commercial Opportunity Gathers Momentum Momentum is growing for Remplir™ in nerve-sparing prostate cancer surgery, with around 100 surgeries now performed using the flagship nerve repair device. Orthocell
Company News 05 Nov 2025 Orthocell Appoints Second Canadian Distributor for Remplirâ„¢ Orthocell has appointed its second distributor in Canada. The appointment completes national coverage across the US$75 million Canadian market, ensuring… Orthocell
Company News 03 Nov 2025 First Remplirâ„¢ Surgical Case Completed in Hong Kong Orthocell has announced the successful completion of the first Remplirâ„¢ surgical case in Hong Kong and the official launch of… Orthocell
